{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T19:50:13Z","timestamp":1770493813338,"version":"3.49.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:p>Acquired resistance to drugs that modulate specific protein functions, such as the human proteasome, presents a significant challenge in targeted therapies. This underscores the importance of devising new methodologies to predict drug binding and potential resistance due to specific protein mutations. In this work, we conducted an extensive computational analysis to ascertain the effects of selected mutations (Ala49Thr, Ala50Val, and Cys52Phe) within the active site of the human proteasome. Specifically, we sought to understand how these mutations might disrupt protein function either by altering protein stability or by impeding interactions with a clinical administered drug. Leveraging molecular dynamics simulations and molecular docking calculations, we assessed the effect of these mutations on protein stability and ligand affinity. Notably, our results indicate that the Cys52Phe mutation critically impacts protein-ligand binding, providing valuable insights into potential proteasome inhibitor resistance.<\/jats:p>","DOI":"10.3389\/fchem.2023.1322628","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T05:59:59Z","timestamp":1704693599000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Decoding the secrets: how conformational and structural regulators inhibit the human 20S proteasome"],"prefix":"10.3389","volume":"11","author":[{"given":"Pedro M. P.","family":"Fernandes","sequence":"first","affiliation":[]},{"given":"Romina A.","family":"Guedes","sequence":"additional","affiliation":[]},{"given":"Bruno L.","family":"Victor","sequence":"additional","affiliation":[]},{"given":"Jorge A. R.","family":"Salvador","sequence":"additional","affiliation":[]},{"given":"Rita C.","family":"Guedes","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"B2","doi-asserted-by":"publisher","first-page":"W530","DOI":"10.1093\/nar\/gkab294","article-title":"PLIP 2021: expanding the scope of the protein\u2013ligand interaction profiler to DNA and RNA","volume":"49","author":"Adasme","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1021\/jm9011092","article-title":"Novel organic proteasome inhibitors identified by virtual and in vitro screening","volume":"53","author":"Basse","year":"2010","journal-title":"J. Med. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1515\/hsz-2012-0212","article-title":"Covalent and non-covalent reversible proteasome inhibition","volume":"393","author":"Beck","year":"2012","journal-title":"bchm"},{"key":"B5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/978-94-015-7658-1_21","article-title":"Interaction models for water in relation to protein hydration","volume-title":"Intermolecular forces: proceedings of the fourteenth Jerusalem symposium on quantum Chemistry and biochemistry held in Jerusalem, Israel, april 13--16, 1981","author":"Berendsen","year":"1981"},{"key":"B6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0010-4655(95)00042-E","article-title":"GROMACS: a message-passing parallel molecular dynamics implementation","volume":"91","author":"Berendsen","year":"1995","journal-title":"Comput. Phys. Commun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1042\/BJ20100383","article-title":"Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S \u03b25-subunit","volume":"430","author":"Blackburn","year":"2010","journal-title":"Biochem. J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1021\/cr0502504","article-title":"20S proteasome and its inhibitors: crystallographic knowledge for drug development","volume":"107","author":"Borissenko","year":"2007","journal-title":"Chem. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"014101","DOI":"10.1063\/1.2408420","article-title":"Canonical sampling through velocity rescaling","volume":"126","author":"Bussi","year":"2007","journal-title":"J. Chem. Phys."},{"key":"B10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"B13","volume-title":"Molecular operating environment (MOE)","year":"2023"},{"key":"B11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.arr.2014.12.003","article-title":"Proteasome activation: an innovative promising approach for delaying aging and retarding age-related diseases","volume":"23","author":"Chondrogianni","year":"2015","journal-title":"Ageing Res. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1402.078","article-title":"Intracellular protein degradation from a vague idea through the lysosome and the ubiquitin-proteasome system and on to human diseases and drug targeting: nobel lecture, december 8, 2004","volume":"1116","author":"Ciechanover","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.molcel.2012.03.026","article-title":"Molecular model of the human 26S proteasome","volume":"46","author":"Da Fonseca","year":"2012","journal-title":"Mol. Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"23305","DOI":"10.1074\/jbc.M802716200","article-title":"Structure of the human 26S proteasome: subunit radial displacements open the gate into the proteolytic core","volume":"283","author":"Da Fonseca","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: an N \u22c5log(N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.biochi.2010.06.023","article-title":"Proteasome inhibitors: dozens of molecules and still counting","volume":"92","author":"de Bettignies","year":"2010","journal-title":"Biochimie"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1186\/1471-2105-11-479","article-title":"Computational analysis and modeling of cleavage by the immunoproteasome and the constitutive proteasome","volume":"11","author":"Diez-Rivero","year":"2010","journal-title":"BMC Bioinforma."},{"key":"B20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jmgm.2010.10.007","article-title":"POVME: an algorithm for measuring binding-pocket volumes","volume":"29","author":"Durrant","year":"2011","journal-title":"J. Mol. Graph. Model."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1021\/ct500381c","article-title":"POVME 2.0: an enhanced tool for determining pocket shape and volume characteristics","volume":"10","author":"Durrant","year":"2014","journal-title":"J. Chem. Theory Comput."},{"key":"B22","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1063\/1.470117","article-title":"A smooth particle mesh Ewald method","volume":"103","author":"Essmann","year":"1995","journal-title":"J. Chem. Phys."},{"key":"B23","unstructured":"EPAR\u2014product information2023"},{"key":"B24","unstructured":"FDA highlights of prescribing information Kyprolis\u00ae (carfilzomib)2023"},{"key":"B25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/leu.2011.256","article-title":"Impaired bortezomib binding to mutant \u03b25 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells","volume":"26","author":"Franke","year":"2012","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.str.2005.11.019","article-title":"Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome","volume":"14","author":"Groll","year":"2006","journal-title":"Structure"},{"key":"B28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/386463a0","article-title":"Structure of 20S proteasome from yeast at 2.4\u00c5 resolution","volume":"386","author":"Groll","year":"1997","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"10976","DOI":"10.1073\/pnas.96.20.10976","article-title":"The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study","volume":"96","author":"Groll","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B30","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S1357-2725(02)00390-4","article-title":"Substrate access and processing by the 20S proteasome core particle","volume":"35","author":"Groll","year":"2003","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.3390\/ijms20215326","article-title":"Chemical patterns of proteasome inhibitors: lessons learned from two decades of drug design","volume":"20","author":"Guedes","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/ph16081096","article-title":"New scaffolds of proteasome inhibitors: boosting anticancer potential by exploiting the synergy of in silico and in vitro methodologies","volume":"16","author":"Guedes","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B33","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/molecules21070927","article-title":"Computational approaches for the discovery of human proteasome inhibitors: an overview","volume":"21","author":"Guedes","year":"2016","journal-title":"Molecules"},{"key":"B34","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.str.2014.11.017","article-title":"Crystal structure of the human 20S proteasome in complex with carfilzomib","volume":"23","author":"Harshbarger","year":"2015","journal-title":"Structure"},{"key":"B35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1021\/ct700301q","article-title":"GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation","volume":"4","author":"Hess","year":"2008","journal-title":"J. Chem. Theory Comput."},{"key":"B36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0955-0674(95)80031-X","article-title":"Ubiquitin, proteasomes, and the regulation of intracellular protein degradation","volume":"7","author":"Hochstrasser","year":"1995","journal-title":"Curr. Opin. Cell Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.cell.2011.12.030","article-title":"Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity","volume":"148","author":"Huber","year":"2012","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","article-title":"Matplotlib: a 2D graphics environment","volume":"9","author":"Hunter","year":"2007","journal-title":"Comput. Sci. Eng."},{"key":"B39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen","volume":"267","author":"Jones","year":"1997","journal-title":"J. Mol. Biol."},{"key":"B40","first-page":"1","article-title":"Structure of the proteasome","volume-title":"Progress in molecular Biology and translational science","author":"Jung","year":"2012"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1002\/bip.360221211","article-title":"Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features","volume":"22","author":"Kabsch","year":"1983","journal-title":"Biopolymers"},{"key":"B42","doi-asserted-by":"publisher","first-page":"10317","DOI":"10.1021\/jm300434z","article-title":"Molecular mechanisms of acquired proteasome inhibitor resistance","volume":"55","author":"Kale","year":"2012","journal-title":"J. Med. Chem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1074\/jbc.274.6.3363","article-title":"The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes","volume":"274","author":"Kisselev","year":"1999","journal-title":"J. Biol. Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"8582","DOI":"10.1074\/jbc.M509043200","article-title":"Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate","volume":"281","author":"Kisselev","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"35869","DOI":"10.1074\/jbc.M303725200","article-title":"The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites","volume":"278","author":"Kisselev","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cbpa.2014.08.012","article-title":"Subunit specific inhibitors of proteasomes and their potential for immunomodulation","volume":"23","author":"Kisselev","year":"2014","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","article-title":"Proteasome inhibitors: an expanding army attacking a unique target","volume":"19","author":"Kisselev","year":"2012","journal-title":"Chem. Biol."},{"key":"B48","first-page":"87","article-title":"Jupyter Notebooks - a publishing format for reproducible computational workflows","volume-title":"Positioning and power in academic publishing: players, agents and agendas","author":"Kluyver","year":"2016"},{"key":"B49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1021\/ci800298z","article-title":"Empirical scoring functions for advanced Protein\u2212Ligand docking with PLANTS","volume":"49","author":"Korb","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"B50","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2012-10-459883","volume":"121","author":"Kortuem","year":"2013","journal-title":"Carfilzomib."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.3390\/molecules27072201","article-title":"Revisiting proteasome inhibitors: molecular underpinnings of their development, mechanisms of resistance and strategies to overcome anti-cancer drug resistance","volume":"27","author":"Leonardo-Sousa","year":"2022","journal-title":"Molecules"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1182\/blood-2012-05-426924","article-title":"Sequence analysis of \u03b2-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone","volume":"120","author":"Lichter","year":"2012","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s008940100045","article-title":"GROMACS 3.0: a package for molecular simulation and trajectory analysis","volume":"7","author":"Lindahl","year":"2001","journal-title":"J. Mol. Model."},{"key":"B55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/cbdd.12298","article-title":"Computational inhibition studies of the human proteasome by argyrin-based analogues with subunit specificity","volume":"84","author":"Loizidou","year":"2014","journal-title":"Chem. Biol. Drug Des."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.exphem.2008.04.013","article-title":"Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma\/leukemia cells derived from Jurkat line","volume":"36","author":"L\u00fc","year":"","journal-title":"Exp. Hematol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.exphem.2009.04.001","article-title":"Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma\/leukemia cells derived from the Jurkat cell line","volume":"37","author":"L\u00fc","year":"2009","journal-title":"Exp. Hematol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1124\/jpet.108.138131","article-title":"Point mutation of the proteasome \u03b25 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma\/leukemia line","volume":"326","author":"L\u00fc","year":"","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3109\/10428194.2013.828351","article-title":"The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma","volume":"55","author":"Manasanch","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"B60","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph8010001","article-title":"Clinical use of proteasome inhibitors in the treatment of multiple myeloma","volume":"8","author":"Merin","year":"2015","journal-title":"Pharmaceuticals"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/med.21312","article-title":"Peptide\u2010based proteasome inhibitors in anticancer drug design","volume":"34","author":"Micale","year":"2014","journal-title":"Med. Res. Rev."},{"key":"B63","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","article-title":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","volume":"18","author":"Niewerth","year":"2015","journal-title":"Drug resist. updat."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1080\/00268978300102851","article-title":"Constant pressure molecular dynamics for molecular systems","volume":"50","author":"Nos\u00e9","year":"1983","journal-title":"Mol. Phys."},{"key":"B65","doi-asserted-by":"publisher","first-page":"12504","DOI":"10.1073\/pnas.95.21.12504","article-title":"Cleavage motifs of the yeast 20S proteasome \u03b2 subunits deduced from digests of enolase","volume":"95","author":"Nussbaum","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit \u03b25 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"B67","first-page":"3","article-title":"Tackling exascale software challenges in molecular dynamics simulations with GROMACS","volume-title":"Lecture notes in computer science (including subseries lecture notes in artificial intelligence and lecture notes in bioinformatics)","author":"P\u00e1ll","year":"2015"},{"key":"B68","doi-asserted-by":"publisher","first-page":"7182","DOI":"10.1063\/1.328693","article-title":"Polymorphic transitions in single crystals: a new molecular dynamics method","volume":"52","author":"Parrinello","year":"1981","journal-title":"J. Appl. Phys."},{"key":"B69","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/bjh.12198","article-title":"A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma","volume":"160","author":"Petrucci","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/bioinformatics\/btt055","article-title":"GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit","volume":"29","author":"Pronk","year":"2013","journal-title":"Bioinformatics"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/leu.2010.137","article-title":"Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress","volume":"24","author":"Ri","year":"2010","journal-title":"Leukemia"},{"key":"B72","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00249-011-0700-9","article-title":"Definition and testing of the GROMOS force-field versions 54A7 and 54B7","volume":"40","author":"Schmid","year":"2011","journal-title":"Eur. Biophys. J."},{"key":"B73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-06752-0_1","article-title":"Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer","volume-title":"Resistance to proteasome inhibitors in cancer","author":"Schmitt","year":"2014"},{"key":"B74","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1126\/science.aaf8993","article-title":"The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design","volume":"353","author":"Schrader","year":"2016","journal-title":"Science"},{"key":"B75","volume-title":"The PyMOL molecular graphics system","author":"Schr\u00f6dinger","year":"2023"},{"key":"B76","doi-asserted-by":"publisher","first-page":"7816","DOI":"10.1073\/pnas.1608050113","article-title":"Structure of the human 26S proteasome at a resolution of 3.9 \u00c5","volume":"113","author":"Schweitzer","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B77","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","article-title":"Ixazomib: first global approval","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.04.008","article-title":"Proteasome inhibitors","volume":"96","author":"Teicher","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"D364","DOI":"10.1093\/nar\/gku1028","article-title":"A series of PDB-related databanks for everyday needs","volume":"43","author":"Touw","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.chembiol.2014.04.010","article-title":"Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor","volume":"21","author":"Trivella","year":"2014","journal-title":"Chem. Biol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0969-2126(02)00748-7","article-title":"The structure of the mammalian 20S proteasome at 2.75 \u00c5 resolution","volume":"10","author":"Unno","year":"2002","journal-title":"Structure"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible, and free","volume":"26","author":"Van Der Spoel","year":"2005","journal-title":"J. Comput. Chem."},{"key":"B83","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-015-0529-1","article-title":"Proteasome inhibitors as experimental therapeutics of autoimmune diseases","volume":"17","author":"Verbrugge","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1124\/jpet.111.187542","article-title":"InactivatingPSMB5Mutations and P-glycoprotein (multidrug resistance-associated protein\/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (Immuno)Proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis","volume":"341","author":"Verbrugge","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1021\/acs.jctc.7b00500","article-title":"POVME 3.0: software for mapping binding pocket flexibility","volume":"13","author":"Wagner","year":"2017","journal-title":"J. Chem. Theory Comput."},{"key":"B86","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.21105\/joss.03021","article-title":"seaborn: statistical data visualization","volume":"6","author":"Waskom","year":"2021","journal-title":"J. Open Source Softw."},{"key":"B87","volume-title":"Gnuplot 5.2. 8: an interactive plotting program","author":"Williams","year":"2019"},{"key":"B88","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1021\/jm9005093","article-title":"Design, synthesis, biological evaluation, and Structure\u2212Activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, Part I: comprehensive understanding of the SAR of \u03b1-amino acid boronates","volume":"52","author":"Zhu","year":"2009","journal-title":"J. Med. Chem."}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2023.1322628\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T06:00:07Z","timestamp":1704693607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2023.1322628\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":88,"alternative-id":["10.3389\/fchem.2023.1322628"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2023.1322628","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"article-number":"1322628"}}